WALDENSTRÖM MACROGLOBULINEMIA
Clinical trials for WALDENSTRÖM MACROGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new WALDENSTRÖM MACROGLOBULINEMIA trials appear
Sign up with your email to follow new studies for WALDENSTRÖM MACROGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to cut lifelong treatment for rare blood cancer
Disease control CompletedThis study tested a combination of three drugs (zanubrutinib, ixazomib, and dexamethasone) in 25 people newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. The treatment was given for up to 24 months and then stopped, aiming to achieve deep remission and redu…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 17, 2026 10:10 UTC
-
New oral combo shows promise for rare blood cancer
Disease control CompletedThis study tested a three-drug oral regimen (thalidomide, cyclophosphamide, and dexamethasone) followed by maintenance therapy (thalidomide and prednisone) in 44 adults newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see how well the treat…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 17, 2026 10:08 UTC
-
New hope for aggressive lymphoma: drug combo shows promise in early trial
Disease control CompletedThis study tested a combination of the drug lenalidomide with standard chemotherapy (called DA-EPOCH-R) in 55 people with a fast-growing type of B-cell lymphoma linked to the MYC gene. The goal was to find the safest dose and see if the combo helps keep the cancer from growing or…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated May 17, 2026 10:07 UTC
-
New drug combo shows promise for blood cancers
Disease control CompletedThis study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with different types of blood cancers like lymphoma and leukemia. The main goal was to check safety and see how well the treatment works. This is an early-stage study, so results help gui…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE1, PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated May 17, 2026 10:06 UTC
-
New Two-Step transplant shows promise for blood cancer patients
Disease control CompletedThis study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. The approach uses chemotherapy and radiation before donor stem cells are given, followed by drugs to prevent graft-versus-host disease. The goal was to control the cancer a…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Stem cell transplant shows promise against rare blood cancer in new trial
Disease control CompletedThis study tested whether a stem cell transplant (using the patient's own cells) could help people with a high-risk form of Waldenström macroglobulinemia, a rare blood cancer, live longer compared to standard chemotherapy. The trial involved 70 adults in China who had not receive…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New hope for rare blood cancer: which drug combo works best?
Disease control CompletedThis study tested two different drug combinations in 35 people newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. One group received cyclophosphamide plus dexamethasone with rituximab, and the other with bortezomib. The goal was to see which combination bett…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 13, 2026 15:58 UTC